A multi-centre general practice trial of a pindolol/clopamide combination ('Viskaldix') in essential hypertension.
A large, open, multi-centre study was carried out in general practice to evaluate the effectiveness and tolerance of a combination of 10 mg pindolol plus 5 mg clopamide, in single tablet form, in the treatment of patients with essential hypertension. Computer analysis of the records of 8989 patients who completed the 8-weeks' study period showed that treatment with the combination product, in a dosage of 1 tablet daily in 83% of the patients, resulted in excellent blood pressure control in the majority (75%) of cases, irrespective of age or previous antihypertensive treatment, and was particularly effective in those with mild to moderate hypertension who had previously not received any therapy. Side-effects were generally not troublesome and only 8.3% of patients stopped treatment for this reason. The most commonly reported side-effects were dizziness, nausea, tiredness and headache.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003005:Clopamide / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; D003005:Clopamide; D010869:Pindolol